80121-65-9

Usage

Uses

Used in Polymer Synthesis:
1,3-Bis(2-hydroxyethyl)adamantane is used as a building block in the synthesis of polymers for its unique adamantane backbone and hydroxyethyl groups, which contribute to the development of novel materials with enhanced properties.
Used in Drug Delivery Systems:
1,3-Bis(2-hydroxyethyl)adamantane is used as a component in drug delivery systems for its potential to improve the efficiency and targeting of therapeutic agents, leveraging its unique structure and functional groups.
Used in Surfactant Development:
In the surfactant industry, 1,3-Bis(2-hydroxyethyl)adamantane is used as a key ingredient for creating new types of surfactants, capitalizing on its molecular structure to enhance the performance and stability of these compounds.
Used in Lubricant Formulation:
1,3-Bis(2-hydroxyethyl)adamantane is utilized in the formulation of lubricants, where its adamantane backbone and hydroxyethyl groups may contribute to improved lubricating properties and performance under various conditions.
Used in Antioxidant Applications:
1,3-Bis(2-hydroxyethyl)adamantane is studied for its potential antioxidant properties, which could be harnessed in various applications to protect materials and biological systems from oxidative damage.
Used in Antimicrobial Applications:
In the field of antimicrobial research, 1,3-Bis(2-hydroxyethyl)adamantane is investigated for its potential to inhibit the growth of microorganisms, offering a new avenue for the development of antimicrobial agents.

Upstream product

• 17768-29-5 dimethyl adamantane-1,3-diyldiacetate 
• 81657-07-0 (3-ethoxycarbonylmethyl-adamantan-1-yl)-acetic acid ethyl ester 
• 17768-28-4 1,3-adamantane diacetic acid 

Downstream Products

• 80121-66-0 1,3-bis[(2-tosyloxyethyloxy)methyl]adamantane 
• 2082-81-7 butane-1,4-diyl di(methacrylate) 

Relevant academic research and scientific papers

Four-Directional synthesis of adamantane derivatives

1-Adamantanemethanol, 1,3-adamantanedimethanol and 1,3,5,7-adamantanetetramethanol were converted into adamantanes functionalized with one or four (2R,1S)-2-formyl-1-cyclopropyl residues using Charette enantioselective cyclopropanation reactions and with one, two or four 4-ethoxy- (or 4-t-butoxy)-3-diazo-2,4- dioxobutyl residues from aldehyde and diazo-acetate ester condensation reactions by 1-directional, 2- directional or 4-directional syntheses. The synthesis of adamantane fused to cyclopentadiene is also reported. 'Equation Presented'.

Synthesis and cytotoxicity of novel simplified eleutherobin analogues as potential antitumour agents

Mixed simplified structures containing the paclitaxel and eleutherobin pharmacophore moieties were analyzed using molecular docking techniques and synthesized based on adamantane and 8-oxabicyclo[3.2.1]octane scaffolds. The crucial role of substituents' stereochemistry in biological activity is discussed. At micromolar concentrations the selected analogues interfered with tubulin dynamics in vitro and in a living organism. Furthermore, new compounds were cytotoxic against human tumour cell lines. The simplified eleutherobin analogues may be considered as prototypes of a new class of antitumour agents.

Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof

The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (I). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.

Synthesis and biological evaluation of memantine nitrates as a potential treatment for neurodegenerative diseases

A series of memantine nitrate derivatives, as dual functional compounds with neuroprotective and vasodilatory activity for neurodegenerative diseases, was designed and synthesized. These compounds combined the memantine skeleton and a nitrate moiety, and thus inhibited the N-methyl-d-aspartic acid receptor and released NO in the central nervous system. The biological evaluation results revealed that the new memantine nitrates were effective in protecting neurons against glutamate-induced injury in vitro. Moreover, memantine nitrates dilated aortic rings against phenylephrine-induced contraction. The structure-activity relationships of neuroprotection and vasodilation were both analyzed. In further studies, compound MN-05 significantly protected cortical neurons by inhibiting Ca2+ influx, reducing free radical production and maintaining the mitochondrial membrane potential. Further research on MN-05 is warranted.

AMANTADINE NITRATE COMPOUND HAVING A NEUROPROTECTIVE EFFECT AND PREPARATION AND MEDICAL USE THEREOF

The present invention relates to amantadine nitrate compounds having neural protective effect, and preparation method and medical use thereof. The compounds have the structure of the general formula (I). The compounds have multifunctional mechanisms, including inhibiting NMDA receptors, releasing NO, inhibiting calcium influxes, and having protective effects on cells particularly neurocytes. The compounds can be used in the preparation of medicaments having a cellular protective effect, for prevention or treatment of the diseases related to such as NMDA receptors and elevation of calcium anions in cells, including the diseases related to neurodegeneration such as Alzheimer's disease, Parkinson's disease, cerebral paralysis and glaucoma, and the diseases related to cardio-cerebral-vascular system such as Parkinson's syndrome combined with cerebral arteriosclerosis, as well as respiratory tract infections caused by influenza virus.

An adamantane-based disubstituted binding motif with picomolar dissociation constants for cucurbit[n]urils in water and related quaternary assemblies

A non-axial centerpiece based on 1,3-disubstituted adamantane was designed, and three new guests were prepared. In the structure of the heterotritopic guests, the central adamantane site was combined with two terminal butyl or 1-adamantyl sites. The new central binding motif displayed an extraordinarily high affinity towards CB8 (Ka = (5.3 ± 0.3) × 1012 M?1 in water) to allow formation of quaternary assemblies with geometries which are dependent on the nature of macrocycles. Based on the individual binding strengths, the replacement of CB7 by CB8 led to inverse arrangements of the quaternary assemblies; i.e., β-CD is capped at the central site by two CB7 units, while the CB8 prefers the central site to be capped with two β-CD units.

Design and synthesis of new adamantyl-substituted antileishmanial ether phospholipids

A series of new 2-[3-(2-alkyloxy-ethyl)-adamantan-1-yl]-ethoxy substituted ether phospholipids was synthesized and their antileishmanial activity was evaluated against Leishmania infantum amastigotes. The majority of the new analogues were significantly l

A CONVENIENT SYNTHESIS OF 1,3-DIVINYLADAMANTANE

1,3-Divinyladamantane was prepared in 30percent overall yield by LiAlH4 reduction of 1,3-bis(carboxymethyl)adamantane, conversion of the resulting diol to the borate ester, and pyrolysis of the ester in vacuo.

Unsaturated esters of adamantane containing diols and thermo-resistant cross-linked polymers therefrom

Diacrylate and dimethacrylate esters corresponding to the formula STR1 wherein R and R' are hydrogen or methyl and A is either a sigma (?) bond; a (CH2)η radical where η is an interger that may vary from one through four; or phenylene, or an alkyl derivative thereof. The new adamantane containing difunctional olefinic monomers can then be polymerized, or copolymerized with other acrylic type olefinic monomers to produce polymers with unusual physical properties, including unusual hardness, inertness to degradable agents, and resistance to heat.

Structure-Anti-Parkinson Activity Relationships in the Aminoadamantanes. Influence of Bridgehead Substitution

A limited series of bridgehead alkyl-, dialkyl- and trialkyl-substituted amantadines was synthesized and tested for potential anti-Parkinson activity as dopamine (DA) agonists.The compounds were evaluated using a battery of three murine bioassays, including stimulation of locomotor activity, induction of circling in animals with unilateral striatal lesions, and reversal of reserpine/α-methyltyrosine induced akinesia.Apparent mechanistic differences were seen between the methyl-substituted series and the ethyl-substituted series.While activities in both series increase with increasing liphophilicity, the methyl series (1b-d), as well as amantadine itself (1a) exhibits only indirect DA agonist activity, as evidenced by ipsilateral rotation in the circling model and no significant difference from control in reversal of akinesia.The ethyl series (1e,f) exhibits weak but reprodicible direct DA agonist activity, as shown by contralateral rotation in the circling assay for 1e and reversal of akinesia by 1e and 1f.The 3-n-propyl derivative (1g) was devoid of any DA agonist activity.